Associated Papers
Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases.
Park SS et al.
Annals of Laboratory Medicine, 2025
40017228 (PubMed )
Supplement: alm-45-3-279-supple2.xlsx › Table_S3
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C et al.
Signal Transduction and Targeted Therapy, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
Exome sequencing of Japanese schizophrenia multiplex families supports the involvement of calcium ion channels.
Toyama M et al.
Plos One, 2022
35536790 (PubMed )
Supplement: pone.0268321.s003.xlsx › Sheet1
Clinicopathologic Characteristics of Grade 2/3 Meningiomas: A Perspective on the Role of Next-Generation Sequencing.
Kim J et al.
Frontiers in Oncology, 2022
35774130 (PubMed )
Supplement: DataSheet_2.xlsx › Sheet2
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer.
Kim J et al.
Cancers, 2020
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Engstrom LD et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Cortot AB et al.
Journal of the National Cancer Institute, 2017
MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.
Montagne R et al.
Oncotarget, 2017
Reproducible Analysis of Post-Translational Modifications in Proteomes--Application to Human Mutations.
Holehouse AS et al.
Plos One, 2015
26659599 (PubMed )
Supplement: pone.0144692.s002.xlsx › suppTable_2.txt
Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
Voortman J et al.
Current Pharmaceutical Design, 2013
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
Select a paper to view details